GSK PLC Sponsored ADR (GSK)
(Delayed Data from NYSE)
$38.84 USD
+0.38 (0.99%)
Updated Jul 5, 2024 04:00 PM ET
After-Market: $38.84 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth F Momentum B VGM
Price, Consensus and EPS Surprise
GSK 38.84 +0.38(0.99%)
Will GSK be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for GSK based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for GSK
GSK Buys Flu, COVID mRNA Jab Rights From Partner CureVac
Biotech Stock Roundup: GSK, CVAC Revise Agreement, Updates From MRNA, RNAC & More
GSK: What are Zacks experts saying now?
Zacks Private Portfolio Services
CHMP Endorses Moderna's (MRNA) mRNA-based RSV Vaccine
CDC Narrows Age Recommendation for Use of RSV Vaccine
Moderna (MRNA) Shares Decline on RSV Vaccine Efficacy Data
Other News for GSK
UK dividends calendar
UK dividends calendar - next 7 days
GLOBAL BROKER RATINGS: Exane raises Lloyds, DZ 'hold' on Givaudan
LONDON BROKER RATINGS: Jefferies cuts Softcat to 'underperform'
UK dividends calendar - next 7 days